PharmAla Biotech Holdings, Inc. (MDMA) AI Stock Analysis

• Market Cap: C$10.89M
• Dividend Yield: N/A
• Average Volume (3M): 208.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.17
• Revenue Growth: -72.51%
• EPS Growth: -170.13%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 108,887,215
• 10 Day Avg. Volume: 94,242
• 30 Day Avg. Volume: 208,173
• PEG Ratio: -0.05
• Price to Book (P/B): 5.47
• Price to Sales (P/S): 22.20
• P/FCF Ratio: -12.84
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: C$0.10 ▼(-13.64% Downside)
• Action: Reiterated Date: 01/09/26
• Date: Action: Reiterated 01/09/26

The score is held back primarily by weak financial performance: deteriorating profitability, negative gross profit, and ongoing cash burn despite improving revenue. Technicals are mixed with only modest near-term strength, and valuation is constrained by losses (negative P/E) with no dividend support.

Positive Factors

Conservative balance sheet / No debt

Zero reported debt meaningfully reduces financial risk and interest burdens, preserving optionality for a biotech requiring R&D spend. Over the next 2–6 months this lowers default/covenant risk and gives management flexibility to prioritize clinical programs or raise capital on better terms.

Sustained revenue growth

Material trailing-twelve-month revenue growth indicates expanding demand or sales traction for the company’s MDMA products or services. Over a multi-month horizon sustained top-line momentum supports scale economics potential and provides a foundation to improve margins if cost controls are implemented.

Cash outflows aligned with accounting losses

Free cash flow tracking closely to net loss suggests reported losses are cash-backed rather than driven by large noncash charges. That alignment improves visibility into real cash burn, aiding near-term planning and reducing risk of surprise noncash adjustments that could complicate funding discussions over the next several months.

Negative Factors

Negative gross profit and large operating losses

Negative gross profit shows core unit economics are currently unfavorable: cost of goods/sales exceed revenue. That structural issue must be corrected via pricing, scale or cost reductions to reach sustainable profitability; otherwise margins will remain a long-term constraint on viability and growth.

Persistent negative operating and free cash flow

Ongoing negative operating and free cash flow depletes liquidity and forces reliance on external funding. Even with no debt today, continued cash consumption will likely require financing within months, which can be dilutive or restrictive and may constrain R&D and commercialization investments.

Deteriorating profitability eroding equity returns

Profitability deterioration year-over-year and materially negative ROE indicate the company is eroding its equity base. Continued losses reduce internal capital, impair ability to self-fund strategy, and increase the likelihood of dilutive raises or cutbacks, undermining long-term shareholder value.

PharmAla Biotech Holdings, Inc. Business Overview & Revenue Model

Company Description

Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.

How the Company Makes Money

PharmAla Biotech Holdings, Inc. generates revenue through the development and sale of MDMA-based pharmaceutical products. The company conducts extensive research and clinical trials to ensure the efficacy and safety of its products, which are then marketed to healthcare providers and institutions. Revenue streams include the licensing of patented compounds, collaboration with research institutions, and potential partnerships with healthcare organizations for distribution and commercialization. Regulatory approvals and advancements in the understanding of psychedelic therapies contribute significantly to the company's earnings potential.

PharmAla Biotech Holdings, Inc. Financial Statement Overview

Summary

Despite TTM revenue growth (+24.6%), the company is deeply unprofitable with negative gross profit and very large operating/net losses, and profitability deteriorated versus 2024. No debt reduces financial risk, but ongoing negative operating cash flow and free cash flow indicate continued cash burn and potential funding needs.

Income Statement

TTM (Trailing-Twelve-Months) revenue improved (+24.6%), but the business remains deeply unprofitable with negative gross profit and very large operating and net losses (net margin roughly -279%). Profitability deteriorated versus 2024, when gross profit was positive and losses were materially smaller, indicating a step-down in cost structure and/or pricing power. Strength is the recent top-line momentum, but margins and earnings quality are the key weakness.

Balance Sheet

The balance sheet is conservatively financed with no debt in the most recent periods (debt-to-equity at 0), which reduces financial risk and gives flexibility. Equity has been maintained at a moderate level (~$2.37M TTM), but returns on equity are meaningfully negative due to ongoing losses, which is a clear pressure point. Overall: low leverage is a strength; persistent losses are eroding the economic value of the equity base.

Cash Flow

Cash generation remains weak: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both negative (about -$0.92M and -$0.93M), and free cash flow declined versus the prior annual period. A modest positive is that free cash flow is roughly in line with net loss (free cash flow to net income near 1x), suggesting losses are not wildly disconnected from cash usage, but the company is still consuming cash and may require continued funding if this persists.

Breakdown	Nov 2025	Nov 2024	Nov 2023	Nov 2022	Aug 2021
Income Statement
Total Revenue	605.50K	1.04M	532.00K	78.07K	0.00
Gross Profit	-845.17K	887.44K	454.10K	75.78K	-303.00
EBITDA	-2.07M	-573.36K	-710.18K	-973.45K	-2.51M
Net Income	-2.18M	-823.60K	-779.81K	-985.58K	-2.51M
Balance Sheet
Total Assets	3.42M	2.90M	2.41M	2.33M	2.79M
Cash, Cash Equivalents and Short-Term Investments	960.66K	419.38K	195.04K	852.14K	2.47M
Total Debt	0.00	0.00	253.54K	0.00	0.00
Total Liabilities	961.73K	916.88K	1.03M	423.78K	138.48K
Stockholders Equity	2.46M	1.98M	1.38M	1.91M	2.66M
Cash Flow
Free Cash Flow	-1.05M	-547.78K	-846.39K	-1.62M	-435.76K
Operating Cash Flow	-1.04M	-321.36K	-339.66K	-625.37K	-173.57K
Investing Cash Flow	-935.27K	-226.42K	-506.74K	-994.87K	629.22K
Financing Cash Flow	1.60M	772.12K	189.29K	0.00	2.02M

PharmAla Biotech Holdings, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.11
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDMA, the sentiment is Negative. The current price of 0.11 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.07 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MDMA.

PharmAla Biotech Holdings, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APS	51 Neutral	C$5.59M	-0.19	―	―	―	90.81%
MDMA	49 Neutral	C$10.89M	-4.98	-85.96%	―	-72.51%	-170.13%
PREV	42 Neutral	C$11.74M	-3.64	21.59%	―	―	-120.00%
PHRM	40 Underperform	C$8.65M	-5.79	-112.32%	―	―	27.35%

PharmAla Biotech Holdings, Inc. Corporate Events

PharmAla Expands MDMA Trial Footprint With Nautilus Sanctuary Data Deal

PharmAla Biotech has signed a Supply & Data Agreement with Nautilus Sanctuary in New York to provide its LaNeo MDMA for a Phase 2 open-label clinical trial using MDMA-assisted therapy to treat post-traumatic stress and adjustment disorders in frontline healthcare workers and first responders. In exchange for donating the drug, PharmAla receives a perpetual, non-exclusive license to de-identified trial data for global regulatory and commercial use, reinforcing its supply-for-data model and expanding its evidence base for LaNeo MDMA, while also completing a separate LaNeo MDMA shipment to University College London for another clinical study.

The Nautilus trial underscores PharmAla’s strategy of supporting high-need mental health populations while building a robust portfolio of clinical data to cement its position as a key supplier of clinical-grade MDMA. By deepening its involvement in U.S. and U.K. research, the company strengthens its industry positioning in psychedelic-assisted therapies, potentially benefiting regulators, clinicians, and patients through accelerated evidence generation on MDMA’s safety and efficacy.

The most recent analyst rating on (TSE:MDMA) stock is a Hold with a C$0.09 price target. To see the full list of analyst forecasts on PharmAla Biotech Holdings, Inc. stock, see the TSE:MDMA Stock Forecast page.

PharmAla Donates MDMA for Fibromyalgia Trial in Major U.S. Research Collaboration

PharmAla Biotech has signed a drug donation agreement with Spaulding Rehabilitation, part of the Mass General Brigham system, to supply its LaNeo MDMA at no cost for a clinical trial investigating MDMA-assisted therapy in fibromyalgia patients. In return, PharmAla will receive a license to the study results, which it can use for public applications such as potential regulatory submissions, while Spaulding retains first publication rights and control over independent intellectual property.

The study, led by Principal Investigator Vitaly Napadow in Boston, will use hyperscan neuroimaging to explore how MDMA-assisted therapy affects brain mechanisms related to pain relief and interpersonal dynamics in fibromyalgia, a chronic condition affecting about 4 million U.S. adults. The collaboration extends PharmAla’s clinical research footprint beyond PTSD into pain and complex, treatment-resistant conditions, potentially strengthening its position in psychedelic-derived therapeutics and expanding the evidence base for MDMA’s analgesic and neuromodulatory effects.

The most recent analyst rating on (TSE:MDMA) stock is a Hold with a C$0.10 price target. To see the full list of analyst forecasts on PharmAla Biotech Holdings, Inc. stock, see the TSE:MDMA Stock Forecast page.

PharmAla Strikes Amsterdam UMC Supply Deal to Advance Commercial-Grade MDMA Packaging

PharmAla Biotech Holdings has signed a binding supply agreement with Amsterdam University Medical Center in the Netherlands to provide LaNeo 40 mg MDMA capsules for a proposed clinical trial. The product will be repackaged into a new single-capsule format as part of the collaboration.

The agreement includes a three-year stability testing program for the single-capsule dosage, designed to generate data needed to develop commercial-grade blister packaging for LaNeo MDMA. This initiative strengthens PharmAla’s European clinical presence and supports its broader commercial strategy by paving the way for more standardized, efficient distribution to research and treatment sites worldwide.

PharmAla already maintains a European value chain to supply LaNeo MDMA for clinical research, and the Amsterdam UMC deal is subject to a separate quality agreement and regulatory approvals. The company continues to position itself as a key provider of clinical-grade MDMA and related molecules to researchers and commercial partners across multiple jurisdictions.

The most recent analyst rating on (TSE:MDMA) stock is a Hold with a C$0.10 price target. To see the full list of analyst forecasts on PharmAla Biotech Holdings, Inc. stock, see the TSE:MDMA Stock Forecast page.

PharmAla Biotech Reshapes Board With Addition of Veteran Financial Executive

PharmAla Biotech Holdings Inc., a specialist in MDMA and MDXX-class psychedelic molecules, develops and manufactures clinical-grade compounds for research and patient treatments while advancing proprietary candidates such as its lead asset ALA-002. The company positions itself as a key supplier to clinical trials and regulated markets, emphasizing close collaboration with regulators as a competitive advantage.

PharmAla has reshaped its board of directors, accepting the resignation of long-time director Dr. Malik Slassi and appointing Montreal-based financial executive Lennie Ryer. Management highlighted Ryer’s deep experience in corporate finance, public-market transitions, and capital raising in life sciences and technology, signaling a push to strengthen governance and financial strategy as PharmAla moves into its next phase of growth.

The most recent analyst rating on (TSE:MDMA) stock is a Hold with a C$0.10 price target. To see the full list of analyst forecasts on PharmAla Biotech Holdings, Inc. stock, see the TSE:MDMA Stock Forecast page.

PharmAla Wins Østfold Hospital Trust Deal to Supply LaNeo MDMA for Depression Trial

PharmAla Biotech has signed a supply agreement with Norway’s Østfold Hospital Trust to provide its LaNeo-branded MDMA for clinical research into MDMA as a potential treatment for major depressive disorder, following a competitive vendor review and extensive due diligence. The deal, which includes both financial and data-sharing components, underscores PharmAla’s strengthening role in Europe’s psychedelic medicine research ecosystem and leverages its established regional value chain, while also enhancing its clinical footprint by encouraging researchers to transition existing trial protocols to its LaNeo MDMA platform through dedicated support tools and potential data-sharing discounts.

The most recent analyst rating on (TSE:MDMA) stock is a Hold with a C$0.11 price target. To see the full list of analyst forecasts on PharmAla Biotech Holdings, Inc. stock, see the TSE:MDMA Stock Forecast page.

PharmAla Biotech Posts Rising Deposits as LaNeo MDMA Demand Builds and Australian Trial Plans Advance

PharmAla Biotech Holdings has released its audited financial statements for the fiscal year ended August 31, 2025, along with unaudited results for the first quarter of fiscal 2026, highlighting steady growth in customer deposits tied to its LaNeo MDMA clinical trial supply business. Customer deposits rose to $276,000 at year-end 2025 and further to $433,000 in Q1 2026, reflecting expanding demand for LaNeo MDMA, particularly in Australia where medical treatments using the product are now reimbursed by private insurers and the Department of Veterans Affairs. Management emphasized that the growing pipeline of clinical trial sales, combined with a recently filed short-form prospectus and an Australian lending partner, will help fund the company’s development efforts and its planned Phase 2a/b clinical trial in Australia, underscoring PharmAla’s strategy to translate its regulatory-first posture and unique supply position into accelerated growth in the psychedelics therapeutics market.

PharmAla Biotech Contracts UK CDMO for ALA-002 Manufacturing

PharmAla Biotech Holdings Inc. has announced that its subsidiary, PharmAla Biotech Australia, has contracted with a UK-based CDMO for the manufacturing of its ALA-002 drug substance. This strategic move is crucial for the company’s upcoming Phase 2 clinical trial in 2026, marking the development of a new Active Pharmaceutical Ingredient for human use since 2022. Additionally, PharmAla has completed a significant shipment of its LaNeo MDMA to Mount Sinai’s Parsons Research Center for clinical research, reinforcing its commitment to advancing psychedelic healing.

PharmAla Biotech Advances with Australian-Made MDMA Capsules

PharmAla Biotech Holdings Inc. has completed release testing of its first Australian-made batch of LaNeo™ MDMA 40mg capsules, marking a significant step in their production capabilities and market expansion. The company also finalized its contract with the Orygen Institute by delivering the last shipment of its Australian-made product to support a Phase 3 Trial on social anxiety in autistic youth, highlighting its commitment to advancing clinical research and its strategic positioning in the global psychedelics market.